YML133W-A Antibody

What is YML133W-A and why is it significant for research?

YML133W-A refers to a putative uncharacterized protein found in Saccharomyces cerevisiae (Baker's yeast), specifically in strain 204508/S288c. This protein has a molecular weight of approximately 17,367 Da and is predicted to be a single-pass membrane protein . The scientific significance of YML133W-A stems from its classification as a "product of dubious gene prediction" that completely overlaps with another gene, YML133C, making it an interesting case study for gene prediction verification and membrane protein research . Researchers investigating YML133W-A often aim to characterize its structure and function, which could potentially provide insights into yeast membrane biology and protein expression pathways. The antibody against this protein serves as a valuable tool for detecting, quantifying, and studying the localization of YML133W-A in experimental settings.

What experimental applications are suitable for YML133W-A antibody?

YML133W-A antibodies have been validated for several standard laboratory techniques in protein research. The primary applications include Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot analysis, which enable researchers to detect and quantify the presence of YML133W-A in various sample types . For Western Blotting, the antibody can be used to identify the target protein based on its molecular weight of 17,367 Da, helping researchers confirm protein expression in yeast cultures or after genetic manipulation experiments. In ELISA applications, the antibody enables quantitative measurement of YML133W-A levels, which can be particularly useful for studying changes in protein expression under different experimental conditions. Additionally, though not explicitly validated in the product documentation, researchers might explore using this antibody for immunoprecipitation, immunohistochemistry, or immunofluorescence studies to further characterize the localization and interactions of YML133W-A within yeast cells.

How should researchers prepare and store YML133W-A antibody for optimal results?

Proper handling and storage of YML133W-A antibody is critical for maintaining its activity and specificity. Upon receipt, the antibody should be stored at either -20°C or -80°C to preserve functionality, with repeated freeze-thaw cycles being strictly avoided as they can lead to degradation and loss of binding capacity . If small volumes of the antibody become entrapped in the seal of the product vial during shipment and storage, a brief centrifugation using a tabletop centrifuge is recommended to dislodge any liquid in the container's cap . The antibody is typically supplied in liquid form with 0.03% Proclin 300 as a preservative, 50% glycerol, and 0.01M PBS at pH 7.4, which helps maintain stability during storage . For experimental use, researchers should prepare working dilutions fresh on the day of the experiment rather than storing diluted antibody for extended periods, as this can lead to reduced performance. When designing experiments, it's advisable to include appropriate positive and negative controls to validate antibody performance and specificity.

What are the key considerations when verifying the specificity of YML133W-A antibody?

Verifying antibody specificity is critical when working with proteins like YML133W-A that are described as "putative uncharacterized" or products of "dubious gene prediction" . Researchers should conduct thorough validation experiments before proceeding with main studies. A comprehensive validation approach includes performing Western blot analysis with both wild-type yeast strains and YML133W-A knockout strains to confirm that the observed signal disappears in the absence of the target protein. Cross-reactivity testing against related yeast proteins, particularly YML133C which overlaps with YML133W-A, is essential to ensure signal specificity . Preabsorption tests, where the antibody is pre-incubated with purified YML133W-A protein before use in immunoassays, can further confirm specificity by demonstrating signal reduction. Additionally, researchers might consider using orthogonal detection methods, such as mass spectrometry, to independently confirm the presence of YML133W-A in samples showing positive antibody signals. Proper validation is particularly important for this protein given its status as a "dubious gene prediction" to avoid experimental artifacts.

What strategies can overcome challenges in detecting low-abundance YML133W-A protein?

Detecting low-abundance membrane proteins like YML133W-A often requires specialized approaches to enhance sensitivity. Researchers can implement enrichment strategies such as subcellular fractionation to isolate membrane components, thereby concentrating the target protein before antibody-based detection . Optimizing protein extraction methods specifically for membrane proteins is crucial, with protocols using appropriate detergents like Triton X-100, NP-40, or specialized membrane protein extraction kits yielding better results than standard protocols. Signal amplification techniques such as tyramide signal amplification (TSA) for immunohistochemistry or chemiluminescent substrates with extended reaction times for Western blots can significantly improve detection limits. For quantitative applications, consider using proximity ligation assays (PLA) which can detect single protein molecules through signal amplification. Additionally, researchers might explore using the YML133W-A antibody in conjunction with modern super-resolution microscopy techniques to visualize low-abundance membrane proteins that might be missed by conventional microscopy. When Western blotting, extended transfer times optimized for membrane proteins and the use of PVDF membranes rather than nitrocellulose can improve signal retention for low-abundance proteins.

How can researchers interpret contradictory results when studying YML133W-A?

When encountering contradictory results in YML133W-A studies, a methodical troubleshooting approach is essential. First, examine technical variables by conducting rigorous controls for antibody specificity, including testing against YML133W-A knockout samples and performing preabsorption controls to ensure signal specificity . Consider the protein's designation as a "product of dubious gene prediction" and its complete overlap with YML133C as potential sources of experimental ambiguity . The membrane localization prediction adds another layer of complexity, as membrane proteins often require specialized extraction and detection methods. Researchers should systematically evaluate whether contradictory results stem from differences in experimental conditions, such as culture conditions affecting protein expression, different extraction methods yielding variable protein recovery, or post-translational modifications affecting antibody recognition. Cross-validation using orthogonal methods is particularly valuable; for instance, if antibody-based detection yields inconsistent results, consider mRNA detection through RT-PCR or protein identification via mass spectrometry as alternative approaches. When publishing findings about YML133W-A, transparency about methodological details and explicit discussion of contradictory results contribute significantly to advancing collective understanding of this uncharacterized protein.

What experimental designs are most effective for studying the potential function of YML133W-A?

Given the uncharacterized nature of YML133W-A, a multi-faceted experimental approach is recommended for functional studies. Begin with gene deletion or CRISPR-based knockout experiments, carefully considering the gene's overlap with YML133C to ensure specific targeting . Phenotypic analysis should examine growth rates, stress responses, and membrane-related functions across various environmental conditions, as membrane proteins often serve as environmental sensors. Protein localization studies using the YML133W-A antibody for immunofluorescence, potentially combined with organelle-specific markers, can provide insights into subcellular distribution and hint at function . Protein-protein interaction studies through co-immunoprecipitation with the YML133W-A antibody, followed by mass spectrometry, can identify binding partners that suggest functional pathways. Consider leveraging technologies such as the yeast two-hybrid system or proximity-dependent biotin identification (BioID) as complementary approaches to mapping the protein's interaction network. For putative membrane proteins, topology mapping using limited proteolysis combined with the YML133W-A antibody can determine protein orientation within the membrane. Additionally, heterologous expression systems and functional complementation experiments in various yeast mutant backgrounds might reveal phenotypes that provide functional insights.

How can researchers distinguish between signals from YML133W-A and its overlapping gene YML133C?

Distinguishing between signals from overlapping genes presents a significant challenge requiring careful experimental design. Researchers should design highly specific PCR primers or probes that target unique regions of each transcript, if they exist, for mRNA-level discrimination . At the protein level, epitope mapping of the YML133W-A antibody is critical to determine if the recognized epitope is present in both proteins or unique to YML133W-A . Consider generating custom antibodies against synthetic peptides representing unique regions of each protein, if such regions can be identified through sequence analysis. CRISPR-based genome editing to introduce epitope tags into the endogenous loci can enable specific detection using anti-tag antibodies rather than relying on antibodies against the native proteins. Mass spectrometry approaches, particularly those focusing on identifying protein-specific peptides, can provide definitive discrimination between the two proteins. Additionally, designing experiments that analyze both proteins simultaneously and correlate their expression patterns may provide insights into whether they represent distinct entities or alternative products of the same genomic region. The comprehensive analysis should acknowledge the "dubious gene prediction" status of YML133W-A and consider the possibility that experimental signals might reflect detection of YML133C rather than a distinct YML133W-A protein.

How does antibody-based research of YML133W-A compare with newer protein detection technologies?

Traditional antibody-based detection of YML133W-A offers established reliability but faces limitations when studying this putative uncharacterized membrane protein . Modern alternatives include CRISPR-Cas9 genome editing to introduce fluorescent protein tags directly into the YML133W-A genomic locus, enabling live-cell imaging without antibodies and avoiding potential cross-reactivity issues with YML133C. Mass spectrometry-based proteomics provides unbiased detection and can distinguish between YML133W-A and YML133C through peptide-specific identification, though sensitivity may be lower than antibody methods for rare proteins. Proximity labeling methods like BioID or APEX can map protein interactions and localization without relying on antibody specificity. The table below compares these methodological approaches for YML133W-A research:

Each method offers distinct advantages for addressing the challenges of studying a dubious gene prediction like YML133W-A, with complementary approaches likely yielding the most comprehensive insights.

What are the optimal protocols for membrane protein extraction when using YML133W-A antibody?

For effective YML133W-A detection, specialized membrane protein extraction protocols are essential given its predicted membrane localization . Standard protein extraction methods often yield poor recovery of membrane proteins, resulting in false negatives during antibody detection. A systematic approach begins with gentle mechanical disruption of yeast cells using glass beads in a buffer containing membrane-protective agents like glycerol. The critical factor is selecting appropriate detergents: for initial screening, test a panel including 1% Triton X-100, 1-2% CHAPS, 0.5% DDM (n-Dodecyl β-D-maltoside), and 1% digitonin, as different membrane proteins show variable solubilization efficiency with different detergents. For YML133W-A specifically, its single-pass membrane prediction suggests that milder detergents might be sufficient for extraction while maintaining the protein's native conformation . Consider the table below for optimizing membrane protein extraction:

After extraction, centrifugation steps should be optimized to concentrate membrane fractions without losing the target protein. For Western blotting applications, transfer conditions may need adjustment, with extended transfer times or specialized buffers for membrane proteins improving detection with the YML133W-A antibody.

How can researchers design conclusive experiments to verify if YML133W-A is truly expressed?

Given YML133W-A's status as a "product of dubious gene prediction" , conclusively verifying its expression requires a multi-faceted approach combining complementary methods. Start with transcriptomic analysis using strand-specific RNA sequencing to determine if the YML133W-A locus is actively transcribed, considering the overlapping YML133C gene. For protein-level verification, implement a comprehensive detection strategy that includes: (1) Western blotting with the YML133W-A antibody using both wild-type and YML133W-A knockout strains as positive and negative controls; (2) immunoprecipitation followed by mass spectrometry to identify peptides unique to YML133W-A that distinguish it from YML133C; and (3) parallel reaction monitoring mass spectrometry targeting predicted unique peptides from both proteins for quantitative comparison. Consider the experimental design matrix below for systematic verification:

Additionally, polysome profiling can determine if the YML133W-A transcript is actively translated, while CRISPR-mediated insertion of epitope tags can enable detection via well-characterized tag antibodies, circumventing potential specificity issues with the YML133W-A antibody.

What emerging technologies might enhance YML133W-A protein characterization beyond antibody-based methods?

The characterization of challenging proteins like YML133W-A is being revolutionized by emerging technologies that complement or potentially replace traditional antibody approaches. CRISPR-based technologies enable precise genomic tagging with minimal functional disruption, allowing researchers to insert split fluorescent proteins or self-labeling enzyme tags (HaloTag, SNAP-tag) that can visualize YML133W-A without antibodies . Advanced mass spectrometry approaches, including data-independent acquisition (DIA) and targeted proteomics, offer increasingly sensitive detection of low-abundance membrane proteins and their post-translational modifications without antibody limitations. For interaction studies, proximity-dependent labeling methods have emerged as powerful tools for mapping protein neighborhoods in living cells. The following table highlights emerging technologies particularly relevant for YML133W-A research:

The AHEAD (Autonomous Hypermutation yEast surfAce Display) technology represents a particularly promising approach, as it leverages yeast surface display to rapidly evolve high-affinity binding proteins through continuous mutation and selection . This could generate novel binding reagents with improved specificity for distinguishing between YML133W-A and YML133C, potentially resolving current detection challenges.